Presenter's Information

Name David Joel Cohen
Country United States
Job Interventional Cardiologist

Other content(s) by This Presenter


  1. Valve in Valve Transcatheter Aortic Valve Replacement with Bioprosthetic Valve Fracture

Slide Presentations

  1. Updated Antiplatelet Therapy After PCI; Prasugrel, AZD6140..;The Future We Can Expect in Routine Practice?
  2. Structural Heart Disease
  3. Randomized Trials vs. Observational Registries: Strengths and Weaknesses
  4. The Nuances of Superiority and Non-Inferiority Trials: Design Considerations, Choice of Endpoints, Cost Effectiveness Analyses
  5. Clopidogrel: Current OASIS7 - Double Is Better !!
  6. Optimal Dosing of Antiplatelet Therapy in Patients With ACS Undergoing an Early Invasive Strategy: Insight from CURRENT-OASIS7 Trial
  7. Cost-Effectiveness of Prasugrel vs. Clopidogrel in ACS
  8. New Thienopyridine Use in ACS and PCI (TRITON-TIMI 38 and Several Subgroup Analyses, PLATO and Several Subgroup Analyses, and CHAMPION Trials)
  9. Nuances of Clinical Trials: Trial Size, Power Analysis, Sub Groups
  10. How to Overcome the Challenges?: New Agents - Prasugrel
  11. When Is TAVI Not Cost-effective?
  12. Management Guideline for Ischemic HF
  13. Why the Adoption of New Agents Is So Low?
  14. Counterpoint: Resisting the Bioabsorbable DES "Bandwagon": A Healthy Dose of Skepticism
  15. CABG Status 2013: (i) Is Off-pump a Real Option? (ii) Aftermath of FREEDOM Results
  16. Early Insights on Cost-effectiveness
  17. Guideline Today: Preload Prior to PCI - Standard of Care
  18. Quality of Life After TAVI: What Do We Know? Why Should You Care?
  19. Six Months Enough!
  20. Cost-Effectiveness of PCI for LM Disease
  21. Quality of Life Outcomes of Transcatheter Mitral Valve Repair: Insights from the COAPT
  22. Failing Bioprosthetic Valves: Valve Fracture, Basilica, and Others
  23. Cost-Effectiveness and Its Clinical Application
  24. Pretreatment with P2Y12 Inhibitors: When Selective vs. Routine Is Used?
  25. Optimizing Antiplatelet Therapy: Balancing Ischemic & Bleeding Risks
  26. Extremely High Risk for TAVR - Insights from QOL and Cost-Effectiveness Studies
  27. Selecting the Appropriate Patients for Long-Term DAPT; Insights from Latest Trials
  28. Bioresorbable Vascular Scaffolds and DAPT Duration: The Longer the Better?
  29. What Is the Optimal Duration of DAPT After PCI/DES?
  30. Finding from PARTNER II Quality of Life Data
  31. ViV TAVR: The Role of Bioprosthetic Valve Fracture
  32. TAVR - Year in Review
  33. ACS and DAPT Duration: Which One and How Long?
  34. Selecting the Appropriate Patients for Long-term DAPT; Insights from PEGASUS TIMI-54
  35. TAVR: Insights from QOL and Economic Evaluation
  36. Bioprosthetic Valve Fracture for Optimizing the Results of Valve in Valve TAVR
  37. PARTNER 2A and SAPIEN 3 Cost-Effectiveness: Cost-effectiveness of TAVR Versus SAVR in Intermediate Risk Patients with Aortic Stenosis
  38. Expanding Role of NOAC in PCI/AF, ACS, and Stable ASCVD: Recent Trials and Next Expectations
  39. Stable CAD & PAD: COMPASS Trial - Will It Change Practice?
  40. TAVR: Insights from Quality of Life and Economic Evaluation
  41. Valve-in-Valve: TAVR with BVF(Bioprosthetic Valve Fracture): In-Depth Techniques and Updated Data
  42. The Emerging Role of NOACs in the Management of Stable CAD and PAD
  43. A Journey of PCSK9 Inhibitors: From Genetics To Clinics
  44. QOL Outcomes of the COAPT Trial
  45. Who Should Not Undergo TAVR? Key Insights from the Pivotal Trials and Registries
CardioVascular Research Foundation (CVRF)
2nd Floor, Asan Institute for Education & Research, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Korea
Tel_82.2.3010.4792 | Fax_82.2.475.6898
재단법인 심장혈관연구재단
대표이사 박승정 | 서울시 송파구 올림픽로43길 88, 서울아산병원 아산교육연구관 2층 | 사업자등록번호 215-82-06387
개인정보 관리책임자_노순정 | 전화번호_02.3010.4792 | 팩스번호_02.475.6898
Copyright © CVRF, Seoul, Korea. All rights reserved.